Overall, it can be visualized that a lot of highlighted regions are on E2 rather than E1. This prompted us to think about what characteristics of E2 make it a good paratope for these antibodies. The dominance of antibodies targeting the E2 protein over E1 in HCV infection reflects multiple factors shaping the immune response and the virus's evolutionary dynamics. This finding aligns with existing literature indicating the immunodominance of E2 in HCV infection. However, it is essential to note limitations encountered during data collection, primarily concerning the lack of detailed reporting on the specific amino acid regions targeted by Abs in the literature.
Firstly, the higher surface exposure of E2 compared to E1 makes it more accessible to immune surveillance, enhancing antibody recognition and response. Additionally, certain viral proteins, including E2, may induce a more robust immune reaction due to their immuno-dominant nature, further amplifying the generation of antibodies against E2. Moreover, E2's pivotal role in mediating viral entry by facilitating receptor binding and fusion makes it a prime target for antibody-mediated neutralization, emphasizing its functional importance in the viral life cycle.
The high genetic variability of HCV contributes to the diversity of epitopes presented by E1 and E2 proteins. While both proteins are critical for viral entry, E2 may exhibit variations that drive differential immune responses among viral strains, possibly leading to the preferential targeting of E2 by the immune system. Moreover, historical research bias and the emphasis on E2's role in vaccine development could also contribute to the disproportionate focus on antibodies against E2. This was an important limitation that was realized during this summary-making process. The research to date has focussed a lot on E2 protein on its own and E1E2 as a dimer has only been starting to get recognized in recent years. Hence it may be only a matter of time before we will see more reports on Abs attaching to E1 as well.Â
Overall, the predominance of antibodies targeting E2 reflects a complex interplay of factors including protein exposure, immunogenicity, functional significance, viral evolution, and research priorities. Understanding these dynamics is crucial for elucidating the immune response to HCV infection and informing the design of effective vaccines and therapeutics targeting the E1-E2 complex. Further research into the epitope specificity and functional implications of antibodies targeting E1 and E2 will deepen our understanding of HCV immunology and aid in the development of novel intervention strategies.